Sodium-Glucose Cotransporter 2 Inhibitor Use in Adults Undergoing Peritoneal Dialysis: A Propensity-Matched Real-World Data Analysis.

ABSTRACT: Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have become key therapeutic agents based on their protective cardiovascular and renal effects. However, their safety and efficacy in patients with kidney failure, especially undergoing peritoneal dialysis (PD), who are a population at very high cardiovascular risk, remain largely unexplored. Methods: We conducted a retrospective global cohort study using the electronic health records of 19,871 adult peritoneal dialysis patients from the Global Collaborative Network TriNetX database. Of these, n = 412 patients used SGLT2is within 3 months after PD initiation. After propensity score matching, n = 367 patients per cohort were evaluated for cardiovascular risk, mortality and adverse events related to SGLT2is-treatmen

SUBMITTER: Amelunxen E 

PROVIDER: S-EPMC12733463 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature